NRX Pharmaceuticals Inc (NRXP) financials · rev $1.2M
NRX Pharmaceuticals Inc (NRXP) rev $1.2M.
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $1.2M | $0 | $0 |
| Cost of Revenue | $505.0K | $0 | $0 |
| Gross Profit | $720.0K | $0 | $0 |
| Operating Income | -$16.2M | -$18.5M | -$27.8M |
| Net Income | -$28.6M | -$25.1M | -$30.1M |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 |
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Total Assets | $13.0M | $3.7M | $7.3M | $25.8M |
| Current Assets | $8.9M | $3.3M | $6.9M | $25.8M |
| Cash & Equivalents | $7.8M | $1.4M | $4.6M | $20.1M |
| Inventory | $0 | $0 | $0 | $0 |
| PP&E | $63.0K | $9.0K | $0 | $0 |
| Total Liabilities | $28.9M | $26.9M | $19.0M | $18.4M |
| Current Liabilities | $28.6M | $21.9M | $19.0M | $15.6M |
| Short-term Debt | $0 | $0 | $9.2M | $7.7M |
| Long-term Debt | $0 | $0 | $9.2M | $2.8M |
| Total Debt | $0 | $0 | $0 | $0 |
| Shareholders' Equity | -$15.9M | -$23.2M | -$11.7M | $7.4M |
| Retained Earnings | -$306.9M | -$278.3M | -$253.1M | -$223.0M |
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating Cash Flow | -$14.1M | -$10.6M | -$21.7M | -$39.8M |
| CapEx | $0 | $0 | $3.0K | $10.0K |
| Investing Cash Flow | -$2.8M | $0 | -$3.0K | -$10.0K |
| Financing Cash Flow | $23.3M | $7.5M | $6.2M | $32.2M |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Net Change in Cash | $6.4M | -$3.2M | -$15.5M | $0 |
| Free Cash Flow | $0 | -$10.6M | -$21.7M | -$39.8M |
FAQ
What is NRXP P/E and revenue?
NRX Pharmaceuticals Inc (NRXP) rev $1.2M.
What is NRXP revenue?
NRX Pharmaceuticals Inc last cached revenue is $1.2M (FY2025).
Is NRXP profitable?
NRX Pharmaceuticals Inc last cached net income is -$28.6M.
What are NRXP total assets?
NRX Pharmaceuticals Inc last cached total assets are $13.0M.
What is NRXP free cash flow?
NRX Pharmaceuticals Inc last cached free cash flow is $0.
Not investment advice. Cached statements, not a live tape.